Wells Fargo Reaffirms Their Hold Rating on United Therapeutics (UTHR)

In a report released on March 3, Benjamin Burnett from Wells Fargo maintained a Hold rating on United Therapeutics, with a price target of $466.00. The company’s shares closed yesterday at $498.65.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Burnett is an analyst with an average return of -3.5% and a 39.08% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Xenon, and Wave Life Sciences.

United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $537.00, a 7.69% upside from current levels. In a report released on March 2, Bank of America Securities also reiterated a Hold rating on the stock with a $569.00 price target.

Based on United Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $790.2 million and a net profit of $364.3 million. In comparison, last year the company earned a revenue of $735.9 million and had a net profit of $301.3 million

Based on the recent corporate insider activity of 254 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year. Most recently, in January 2026, MICHAEL BENKOWITZ, the President & COO of UTHR sold 376.00 shares for a total of $180,735.68.